The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is an ...
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...
The drug developed by Boston-based Vertex Pharmaceuticals blocks sodium channels in the peripheral nervous system, preventing ...